Susquehanna International Group, LLP Genprex, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $24,619 - $1.08 Million	18,651 Added 46.42%	58,832 $83,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $97,437 - $175,844	-76,123 Reduced 65.45%	40,181 $56,000
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $96,017 - $214,253	-79,353 Reduced 40.56%	116,304 $152,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $18,803 - $24,393	7,260 Added 3.85%	195,657 $524,000
Q2 2021 Aug 11, 2021	SELL	$3.11 - $4.87 $440,018 - $689,031	-141,485 Reduced 42.89%	188,397 $631,000
Q1 2021 May 17, 2021	BUY	$3.66 - $7.67 $192,259 - $402,905	52,530 Added 18.94%	329,882 $1.42 Million
Q4 2020 Feb 16, 2021	SELL	$3.03 - $5.51 $191,574 - $348,375	-63,226 Reduced 18.56%	277,352 $1.15 Million
Q3 2020 Nov 16, 2020	BUY	$2.9 - $4.29 $61,572 - $91,085	21,232 Added 6.65%	340,578 $1.14 Million
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $464,903 - $850,376	233,620 Added 272.52%	319,346 $1 Million
Q1 2020 May 15, 2020	BUY	$0.28 - $6.23 $24,003 - $534,072	85,726 New	85,726 $207,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.